Intensity Therapeutics/$INTS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Intensity Therapeutics
Intensity Therapeutics Inc . is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
Ticker
$INTS
Sector
Primary listing
Employees
6
Headquarters
Website
INTS Metrics
BasicAdvanced
$13m
-
-$8.56
4.23
-
Price and volume
Market cap
$13m
Beta
4.23
52-week high
$8.06
52-week low
$5.00
Average daily volume
28k
Financial strength
Current ratio
5.922
Quick ratio
5.555
Long term debt to equity
0.665
Total debt to equity
0.926
Profitability
Management effectiveness
Return on assets (TTM)
-79.25%
Return on equity (TTM)
-156.90%
Valuation
Price to book
1.11
Price to tangible book (TTM)
1.11
Price to free cash flow (TTM)
-0.768
Free cash flow yield (TTM)
-130.16%
Free cash flow per share (TTM)
-6.807
Growth
Earnings per share change (TTM)
-70.74%
3-year earnings per share growth (CAGR)
-46.41%
INTS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Intensity Therapeutics stock?
Intensity Therapeutics (INTS) has a market cap of $13M as of April 28, 2026.
What is the P/E ratio for Intensity Therapeutics stock?
The price to earnings (P/E) ratio for Intensity Therapeutics (INTS) stock is 0 as of April 28, 2026.
Does Intensity Therapeutics stock pay dividends?
No, Intensity Therapeutics (INTS) stock does not pay dividends to its shareholders as of April 28, 2026.
When is the next Intensity Therapeutics dividend payment date?
Intensity Therapeutics (INTS) stock does not pay dividends to its shareholders.
What is the beta indicator for Intensity Therapeutics?
Intensity Therapeutics (INTS) has a beta rating of 4.23. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.